These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 15654353

  • 1. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C.
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [Abstract] [Full Text] [Related]

  • 2. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH, Linch DC.
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [Abstract] [Full Text] [Related]

  • 3. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
    Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I.
    Bone Marrow Transplant; 2006 Feb; 37(3):277-82. PubMed ID: 16400345
    [Abstract] [Full Text] [Related]

  • 4. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA.
    Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C.
    Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
    [Abstract] [Full Text] [Related]

  • 6. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V.
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [Abstract] [Full Text] [Related]

  • 8. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 11. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 12. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F, Cavenaghi L, de Melo CM.
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma.
    Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Sep; 30(5):273-8. PubMed ID: 12209348
    [Abstract] [Full Text] [Related]

  • 14. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E, Mahlamäki E, Nousiainen T.
    Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
    [Abstract] [Full Text] [Related]

  • 15. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
    Liu JH, Chen CC, Bai LY, Chao SC, Chang MS, Lin JS.
    J Chin Med Assoc; 2008 Jun; 71(6):279-85. PubMed ID: 18567557
    [Abstract] [Full Text] [Related]

  • 16. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 17. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C.
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [Abstract] [Full Text] [Related]

  • 18. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 19. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B.
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [Abstract] [Full Text] [Related]

  • 20. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S.
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.